SCHEMBL3456876

SCHEMBL3456876

Cc1cc(C#N)ccc1N1CCN(C(=O)[C@H]2CCN(C(=NC#N)N3CCCCC3)C[C@@H]2C(=O)O)CC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSK P43235 6/20 0.40
CTSS P25774 5/20 0.40
CTSB P07858 5/20 0.36
TSHR P16473 1/20 0.36
ADAM10 O14672 1/20 0.36
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
MMP14 P50281 1/20 0.36
ADAM17 P78536 1/20 0.36
SLC6A9 P48067 1/20 0.36
LMNA P02545 1/20 0.35
FASN P49327 2/20 0.35
AR P10275 2/20 0.35
DPP4 P27487 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35
EGLN1 Q9GZT9 1/20 0.34
CSF1R P07333 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6024520 1.00 CTSK (0.40) CTSKCTSSCTSBTSHRADAM10
SCHEMBL3456872 1.00 CTSK (0.40) CTSKCTSSCTSBTSHRADAM10
SCHEMBL5623199 0.91 ADAM10 (0.43) CTSKCTSSCTSBADAM10MMP2
SCHEMBL2171830 0.91 CTSK (0.40) CTSKCTSSCTSBTSHRADAM10
SCHEMBL5621928 0.91 ADAM10 (0.43) CTSKCTSSCTSBADAM10MMP2
SCHEMBL2174467 0.91 ADAM10 (0.43) CTSKCTSSCTSBADAM10MMP2
SCHEMBL2175080 0.91 ADAM10 (0.43) CTSKCTSSCTSBADAM10MMP2
SCHEMBL2175075 0.91 ADAM10 (0.43) CTSKCTSSCTSBADAM10MMP2
SCHEMBL2174463 0.91 ADAM10 (0.43) CTSKCTSSCTSBADAM10MMP2
SCHEMBL2172423 0.90 ADAM10 (0.44) CTSKCTSSCTSBADAM10MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150025056-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION (US) 2015-01-22 US disclosed
US-8853243-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2014-10-07 US disclosed
EP-2264030-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases Incyte Corporation (US) 2010-12-22 EP disclosed
US-20080167288-A1 Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases LNCYTE CORPORATION (US) 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025056-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP2, MMP14 CTSK 76/4885CTSS 42/4885CTSB 66/4885
US-20080167288-A1 Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases MMP25, MMP9, MMP24 CTSK 130/4885CTSS 52/4885CTSB 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.